Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Key trials in bladder cancer from ASCO GU 2022

Guru Sonpavde • 18 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Enfortumab vedotin
EV-103

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, discusses some of the key trial data presented at ASCO GU 2022, including the EV-103 trial on enfortumab vedotin for muscle invasive bladder cancer (NCT03288545), as well as the potential of PARP inhibitors in this field. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Guru Sonpavde

1:36
Liquid biopsies and tumor-informed ctDNA profiling in metastatic urothelial carcinoma
Guru Sonpavde • 18 Feb 2022
1:40
Safety results from Phase 3b STRONG trial of durvalumab in patients with urinary tract carcinoma
Guru Sonpavde • 18 Feb 2022
1:34
Phase 2 trial of CV301 vaccine plus atezolizumab in advanced urothelial carcinoma
Guru Sonpavde • 18 Feb 2022
0:50
Role of vaccines in urothelial carcinoma
Guru Sonpavde • 18 Feb 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals